In its largest M&A deal, Incyte adds late-stage bleeding candidate via Vega buy

Incyte’s deal for $1.25 billion up front to acquire the Vega subsidiary of venture-backed Star, the biotech’s largest M&A deal thus far, will add a late-stage program for bleeding disorder von Willebrand disease to its hematology pipeline.

Incyte Corp. (NASDAQ:INCY) will acquire Vega Therapeutics Inc. and gain PROS1-targeting mAb VGA039, now in the global Phase III VIVID-6 trial as prophylaxis for von Willebrand. Data are due in early 2029, and a launch could soon follow, Incyte President and Head of R&D Pablo Cagnoni said on a conference call Monday. The molecule has breakthrough therapy, fast track, orphan drug and rare pediatric disease designations from FDA for the disease...